Phenom Named Strategic Leader in Fosway’s 9-Grid™ for Talent Acquisition 2023 for Third Consecutive Year
22.5.2023 12:00:00 EEST | Business Wire | Press release
Phenom has been named a Strategic Leader in the 2023 Fosway 9-GridTM for Talent Acquisition for the third consecutive year, proving its ability to deliver higher levels of innovation, customer impact and advocacy compared to alternatives in the market. Fosway identifies Strategic Leaders as companies that provide a rich suite of capability across a broad scope of features and have the sophistication to consistently meet the needs of complex enterprise-scale customers.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20230522005161/en/
Strategic Leader position reaffirms Phenom and its Intelligent Talent Experience platform’s consistent ability to serve EMEA’s largest companies’ complex talent demands. (Graphic: Business Wire)
Job vacancy rates recently reached record highs and the competitive talent market remains a priority on the European Union’s policy agenda, according to a European Labour Authority report. To better connect with candidates and quickly fill open roles in a scalable, sustainable way, CHROs and CEOs from today’s leading enterprises are choosing holistic solutions that leverage intelligence, automation and experience to reduce repetitive tasks, increase recruiter efficiency and hyper-personalize every part of the talent journey.
“Artificial intelligence (AI) is accelerating disruption in the TA market,” said David Wilson, CEO, Fosway Group. “Phenom’s position as a Strategic Leader on the 2023 Fosway 9-Grid™ for Talent Acquisition reflects the company’s continued innovation in AI and the candidate and talent experience. Recent acquisitions continue to give the company even greater traction in the European market.”
More than 500 global, diverse enterprises use Phenom’s vast network of data, contextual industry models and deep learning to achieve measurable, defensible results. Case studies of customers using the Intelligent Talent Experience platform document their ability to:
- Generate 11X more internal and external applications and achieved a 50% reduction in time to apply
- Drive a 176% increase in applications and 165% increase in hires YOY
- Deliver 8X more candidates and 20% faster hires
- Save up to 78% of recruiters’ time with automated screening and scheduling
- Decrease time to schedule an interview 98% (from 5 minutes to 5 seconds) with automation
- Increase recruiter productivity 567% and reduce agency spend
- Cut 65 days off time to hire
“Phenom continues to deliver innovation, scale technology and elevate customer support to solve the most complex talent demands of the largest enterprises across Europe,” said Mahe Bayireddi, CEO and co-founder of Phenom. “We are fully invested in the success of our customers’ teams, their outcomes and the incredible impact they’re able to drive for talent acquisition and management — and the business as a whole.”
In addition to their existing talent acquisition technology — including Career Site, CMS, CRM, Video Assessments and AI Scheduling — Phenom recently announced Phenom X+, a new platform-wide generative AI capability that bolsters efficiencies by automating content creation, surfacing actionable intelligence, and eliminating time-consuming tasks. Phenom also unveiled 18 platform intelligence and automation innovations to further transform the way employers teams hire, develop and retain talent.
Platform innovation highlights include:
- Generative AI for TA — providing sourcers, recruiters, talent marketers, and other talent acquisition professionals the ability to generate personalized content that delights candidates and dramatically speeds up the hiring process by eliminating time-consuming, manual work.
- High-Volume Hiring — automating job discovery, application submission, and offering extension processes for frontline and hourly workers.
- Automation Engine — giving organizations the backend interface and control needed to configure and iterate on hiring workflows – complete with intelligence for ongoing monitoring and qualitative analysis of performance, plus recommendations to optimize in real-time.
- Interview Intelligence — eliminating the black box of the interview process by providing transcripts, key takeaways, and actionable guidance to the hiring team to move forward with decisions faster.
- Workforce Intelligence — providing context and oversight to HR teams within their organization, including hiring trends, churn rate, retention risks and high performers, to improve talent onboarding, development and retention.
- Candidate Hub – bringing transparency to candidates throughout the hiring process, making it easy to discover relevant roles, understand hiring status, prepare for interviews, and reschedule when conflicts arise.
Companies across EMEA are successfully adopting Phenom’s Intelligent Talent Experience platform to help candidates find and choose them faster, employees develop their skills and evolve, recruiters become wildly productive, managers build stronger-performing teams, HR align employee development with company goals and HRIS create a holistic tech infrastructure through seamless integrations.
To learn more about Phenom’s Strategic Leader position, read this blog.
To see the Phenom Intelligent Talent Experience platform in action, request a demo.
About the Fosway 9-Grid™
Fosway Group is Europe’s #1 HR industry analyst. The Fosway 9-Grid™ provides a unique assessment of the principal learning and talent supply options available to organizations in EMEA. The analysis is based on extensive independent research and insights from Fosway’s Corporate Research Network of over 250 organizations, including BP, HSBC, PwC, RBS, Sanofi, Shell, and Vodafone. Visit the Fosway website at www.fosway.com.
About Phenom
Phenom has a purpose of helping a billion people find the right job. Through AI-powered talent experiences, employers are using Phenom to hire employees faster, develop them to their full potential, and retain them longer. The Phenom Intelligent Talent Experience platform seamlessly connects candidates, employees, recruiters, hiring managers, HR and HRIS — empowering over 500 diverse and global enterprises with innovative products including Phenom Career Site, Chatbot, CMS, CRM, AI Scheduling, Video Assessments, Campaigns, University Recruiting, Talent Marketplace, Career Pathing, Gigs, Mentoring, and Referrals.
Phenom has earned accolades including: Inc. 5000’s fastest-growing companies (3 consecutive years), Deloitte Technology's Fast 500 (4 consecutive years), five Brandon Hall ‘Excellence in Technology’ awards including Gold for ‘Best Advance in AI for Business Impact,’ Business Intelligence Group's Artificial Intelligence Excellence Awards (3 consecutive years), and a regional Timmy Award for launching and optimizing HelpOneBillion.com (2020).
Headquartered in Greater Philadelphia, Phenom also has offices in India, Israel, the Netherlands, Germany and the United Kingdom.
For more information, please visit www.phenom.com. Connect with Phenom on LinkedIn, Twitter, Facebook, YouTube and Instagram.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20230522005161/en/
Contact information
Media:
Jennifer Lyons
Director, Global Communications
267-379-5066
jennifer.lyons@phenompeople.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Corcept Announces CHMP Opinion Recommending EU Marketing Authorization for Lifyorli ® (Relacorilant)18.9.2026 15:00:00 EEST | Press release
Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the hormone cortisol, today announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has recommended that the European Commission (EC) should approve relacorilant, combined with the chemotherapy drug nab-paclitaxel, for the treatment of patients with platinum-resistant ovarian cancer. The CHMP’s recommendation is based on positive data from Corcept’s Phase 2 and pivotal Phase 3 ROSELLA trials, in which patients receiving relacorilant combined with nab-paclitaxel experienced improved progression-free and overall survival compared to patients who received nab-paclitaxel alone. The safety profile of relacorilant plus nab-paclitaxel in these trials was consistent with the safety profile of nab-paclitaxel monoth
Enhertu ® Recommended for Approval in the EU by CHMP as Adjuvant Treatment for Patients with Residual Disease After Neoadjuvant Treatment for HER2 Positive Early Breast Cancer18.9.2026 15:00:00 EEST | Press release
Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the adjuvant treatment of adult patients with resected HER2 positive breast cancer who have residual invasive disease after neoadjuvant taxane-based and HER2 targeted treatment. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from the DESTINY-Breast05 phase 3 trial presented at the 2025 European Society for Medical Oncology (#ESMO25) Congress and subsequently published in The New England Journal of Medicine. The recommendation will now be reviewed by the European Commission, which has the authority to grant marketing authorizations for medicines in the EU. In DES
CHMP Recommends EU Approval of New Indication for Alfasigma’s Jyseleca ® (filgotinib), Treatment of Adults With Axial Spondyloarthritis18.9.2026 13:58:00 EEST | Press release
Alfasigma S.p.A, a global pharmaceutical company with a focus on innovation in rare disease and specialty care in areas where there is significant unmet patient need, today announced that the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) has issued a positive opinion for Jyseleca® (filgotinib), an oral, once-daily JAK1 preferential inhibitor, for the treatment of patients with active axial spondyloarthritis (axSpA), both non-radiographic and radiographic forms of the disease, who have responded inadequately to conventional therapy. Following this positive opinion, the application is now referred to the European Commission (EC) for final action. The EC’s decision is expected in the next weeks. “At present, half of people living with axSpA fail to adequately respond to treatment, leaving them with years of preventable struggle with persistent pain and other impactful symptoms,” said Daniele D'Ambrosio, Chief Development Officer, Alfasigma. “This
IMPACT Therapeutics and Pharmanovia Announce Positive CHMP Opinion for Senaparib, as a Potential First-Line Maintenance Treatment of Advanced High-Grade Epithelial Ovarian, Fallopian Tube, and Primary Peritoneal Cancer18.9.2026 13:38:00 EEST | Press release
For business and medical media only This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260918325771/en/ Stephan Eder, CEO, Pharmanovia IMPACT Therapeutics (07630.HK), a commercial-stage biotechnology company focused on the discovery and development of targeted anti-cancer therapeutics based on synthetic lethality mechanisms, together with global specialty pharmaceutical company Pharmanovia, today jointly announce that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion recommending the granting of a Marketing Authorisation (MA) for the medicinal product Sepalna® (senaparib) intended for the maintenance treatment of advance epithelial ovarian, fallopian tube and primary peritoneal cancer. Following the CHMP’s recommendation for approval, senaparib will be submitted to the European Commission (EC) for final decision. Once approved by the EC, senaparib will
Estithmar Holding Announces Completion of 48.68% Stake Transfer in Shahba Bank to Masaref Holding, a Subsidiary of Estithmar Capital18.9.2026 12:48:00 EEST | Press release
Estithmar Holding Q.P.S.C. announced the completion of the transfer of a 48.68% stake in Shahba Bank to Masaref Holding LLC, subsidiary of Estithmar Capital, Estithmar Holding’s financial services and investments arm. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260918807909/en/ Estithmar Holding Announces Completion of 48.68% Stake Transfer in Shahba Bank to Masaref Holding, a Subsidiary of Estithmar Capital (Photo: AETOSWire) As a shareholder, Masaref Holding intends to support the assessment of proposals aimed at strengthening Shahba Bank’s financial, operational and technological capabilities, including potential capital enhancement, branch network expansion, and the development of products and services for individuals, businesses and SMEs. The proposals may include modernizing banking and operational systems, develop digital services, and strengthen governance, compliance, risk management and cybersecurity to enhance
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
